POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS
- Author
- VELLINGA, M. M1 ; CASTELIJNS, J. A2 ; BARKHOF, F2 ; UITDEHAAG, B. M. J1 3 ; POLMAN, C. H1
[1] Department of Neurology, MS Center, VU University Medical Center, Amsterdam, Netherlands
[2] Department of Radiology, MS Center, VU University Medical Center, Amsterdam, Netherlands
[3] Department of Clinical Epidemiology and Biostatistics, MS Center, VU University Medical Center, Amsterdam, Netherlands - Source
Neurology. 2008, Vol 70, Num 13, pp 1150-1151, 2 p ; 2 ; ref : 7 ref
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Homme Natalizumab Pathologie du système nerveux Rebond Traitement
- Keyword (en)
- Human Natalizumab Nervous system diseases Rebound Treatment
- Keyword (es)
- Hombre Natalizumab Sistema nervioso patología Rebote Tratamiento
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17F Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
- Discipline
- Neurology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20259890
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1212/01.wnl.0000265393.03231.e5 
https://dx.doi.org/10.1212/01.wnl.0000265393.03231.e5
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:9:\"\u0000*\u0000jtitle\";s:9:\"Neurology\";s:9:\"\u0000*\u0000stitle\";s:9:\"Neurology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1150\";s:8:\"\u0000*\u0000epage\";s:4:\"1151\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-3878\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"VELLINGA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:16:\"CASTELIJNS, J. A\";i:1;s:10:\"BARKHOF, F\";i:2;s:18:\"UITDEHAAG, B. M. J\";i:3;s:12:\"POLMAN, C. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEURAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"2\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:9:\"\u0000*\u0000jtitle\";s:9:\"Neurology\";s:9:\"\u0000*\u0000stitle\";s:9:\"Neurology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1150\";s:8:\"\u0000*\u0000epage\";s:4:\"1151\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-3878\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"VELLINGA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:16:\"CASTELIJNS, J. A\";i:1;s:10:\"BARKHOF, F\";i:2;s:18:\"UITDEHAAG, B. M. J\";i:3;s:12:\"POLMAN, C. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEURAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"2\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:9:\"\u0000*\u0000jtitle\";s:9:\"Neurology\";s:9:\"\u0000*\u0000stitle\";s:9:\"Neurology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1150\";s:8:\"\u0000*\u0000epage\";s:4:\"1151\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-3878\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"VELLINGA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:16:\"CASTELIJNS, J. A\";i:1;s:10:\"BARKHOF, F\";i:2;s:18:\"UITDEHAAG, B. M. J\";i:3;s:12:\"POLMAN, C. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEURAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"2\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:9:\"\u0000*\u0000jtitle\";s:9:\"Neurology\";s:9:\"\u0000*\u0000stitle\";s:9:\"Neurology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1150\";s:8:\"\u0000*\u0000epage\";s:4:\"1151\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-3878\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"VELLINGA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:16:\"CASTELIJNS, J. A\";i:1;s:10:\"BARKHOF, F\";i:2;s:18:\"UITDEHAAG, B. M. J\";i:3;s:12:\"POLMAN, C. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEURAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"2\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:34:\"10.1212\/01.wnl.0000265393.03231.e5\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:9:\"\u0000*\u0000jtitle\";s:9:\"Neurology\";s:9:\"\u0000*\u0000stitle\";s:9:\"Neurology\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"70\";s:8:\"\u0000*\u0000issue\";s:2:\"13\";s:8:\"\u0000*\u0000spage\";s:4:\"1150\";s:8:\"\u0000*\u0000epage\";s:4:\"1151\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0028-3878\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"VELLINGA\";s:10:\"\u0000*\u0000aufirst\";s:4:\"M. M\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:4:{i:0;s:16:\"CASTELIJNS, J. A\";i:1;s:10:\"BARKHOF, F\";i:2;s:18:\"UITDEHAAG, B. M. J\";i:3;s:12:\"POLMAN, C. H\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEURAI\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:1:\"2\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:90:\"POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"2\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
